Nooglutyl, or Nooglutil, N-5-[oxynicotinoyl]-L-glutamic acid, ONK-10, OHK-10, is an experimental compound recently developed in Russia at the Research Institute of Pharmacology, Russian Academy of Medical Sciences. It is currently classified by researchers as a nootropic agent. Nooglutyl is currently being investigated for its potential as treatment and management for a variety of neurological and psychological disorders.
The patent of Nooglutyl was only granted as recently as October 2011, four years after it was filed. Based on its structure, Nooglutyl appears to be another glutamate analogue akin to the racetam family, particulary Piracetam. Some studies indicate that it is a positive allosteric modulator of the AMPA receptors so one can make a reasonable assumption that its effects may also be similar to racetams and ampakines.
Since Nooglutyl is a fairly new compound, there are no existing data about its effects on humans. It also seems as if no human studies have been conducted yet, or at least the studies are yet to be published. However, there are a number of studies conducted on lab animals and the results have been very promising. Most of the studies indicate that Nooglutyl has the potential to be considered as one of the most potent and effective cognitive enhancers.
The following are some of the results based on the animal studies that were conducted on Nooglutyl.
A BETTER NOOTROPIC
Even though this particular study was conducted way back in 1994, it was able to establish, perhaps for the first time that Nooglutyl has been determined to have effective and potent nootropic properties. Nooglutyl was observed to have a positive effect on memory creation and retention, and it was also able to improve most of the cognitive processes of the lab animals. The study also suggested that it had antiamnesic and antihypoxic abilities.
The primary objective of this study is to compare the effectiveness of Nooglutyl to existing cognitive enhancing at that time like Nootropil, Meclofenoxate, Meksidol, Pyritinol, and Clerigil. The test concluded that Nooglutyl was more effective than the other nootropic drugs in the study. A subsequent study comparing the effectiveness of Nooglutyl to other nootropics concluded that Nooglutyl surpasses the neuroprotective properties other nootropics.
OTHER POTENTIAL MEDICAL APPLICATIONS
A study conducted some four years later found that its antihypoxic abilities make it a viable treatment for memory impairment due to hypoxia and cerebral ischemia. The laboratory mice underwent bilateral occlusion of the common carotid arteries and the administration of Nooglutyl not only increased their survival rates, but also was able to prevent the occurrence of mnestic disorders. In a related study, Nooglutyl has also been observed to have the ability to facilitate the recovery of rats with artificially induced hemorrhagic stroke.
Among the promising results from animal studies conducted on Nooglutyl include its ability to boost the mental energy and cognitive processes of aged mice. The rats in this study also showed better locomotor activity and decreased anxiety. Other results conclude that Nooglutyl can help recovering alcoholics, and it appears to also have anti-motion sickness properties.
While the studies on Nooglutyl may appear to be mostly rosy, there are some studies though that seems to expose some of its weaknesses. One of the more recent studies that show Nooglutyl has a very short half life of between 0.37hr to 2.3hr in the experimental animals. Nooglutyl also appears to have a low bioavailability when it is administered orally. One study however, showed that tableted Nooglutyl is efficiently absorbed through oral administration by rabbits. Unless, formal human trials are undertaken, the issue of low biavailability cannot be definitively confirmed or disproved.
The good news perhaps to some of these misgivings is that since Nooglutyl is still a work in progress, researchers might be able to find ways in order to address the issue of half-life and bioavailability. Time will tell if the potential shown by Nooglutyl as a cognitive enhancer carries over to human trials. Until then, it would seem that from the looks of it, nootropic users may have to wait a little longer before Nooglutyl is released to the public.